Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Type 1 Diabetes Mellitus Condition: Suggested guidelines for beginning dose |
Dose: Subcutaneous – 0.5-1 unit/kg/day Frequency: in divided doses Note: nonobese may require 0.4-0.6 unit/kg/day; obese may require 0.8-1.2 units/kg/day; change insulin doses in small increments (2 unit change); look for consistent pattern in blood sugars for greater than 3 days; dosage of human insulin must be based on results of blood and urine glucose tests and carefully individualized; dose adjustments should be based on regular blood glucose testing; adjust to achieve appropriate glucose control. |
|
Indication: Type 2 Diabetes Mellitus Age: Adult |
Dose: Subcutaneous – 0.3-0.6 IU/kg/day Frequency: may be given in 1-2 divided doses Note: Dose should be individualized, to be adjusted according to patient's needs; change insulin doses in small increments (2-4 unit change); look for consistent pattern in blood sugars for greater than 3 days; dosage of human insulin must be based on results of blood and urine glucose tests and carefully individualized; dose adjustments should be based on regular blood glucose testing; adjust to achieve appropriate glucose control. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Type 1 Diabetes Mellitus Age: less than 12 years |
Dose: Subcutaneous Injection – Safety and efficacy not established Note: Safety and efficacy not established |
|
Indication: Type 1 Diabetes Mellitus Age: greater than 12 years |
Dose: Subcutaneous Injection – 0.5-1 unit/kg/day Note: Suggested dose is 0.5-1 unit/kg/day; use adult dosing; usual daily maintenance range in adolescents is less than 1.2 units/kg/day during growth spurts |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal impairment |
Dose: Form not specified – Dose adjustment may be needed Note: Renal impairment: Dose adjustments may be needed. |
Administration
- Follow injection schedule
- Rotate injection sites
Side Effect
- Allergic reactions
- Injection site reaction
- lipodystrophy
- pruritus
- rash
- lipoatrophy
- hypokalaemia
- blurred vision
- Hypoglycaemia
- insulin resistance
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Beta-blockers (Propranolol, Metoprolol, Atenolol, Bisoprolol, Carvedilol, Nadolol, Timolol, Sotalol)
|
Possible absence of hypoglycaemic warning symptoms
|
|
Corticosteroids (Prednisone, Prednisolone, Methylprednisolone, Dexamethasone, Hydrocortisone), Danazol, Diazoxide, Diuretics, Glucagon, Isoniazid, Phenothiazine derivatives, Somatropin, Sympathomimetic agents, Thyroid hormones, Oestrogens, Progestins, Protease inhibitors, Atypical Antipsychotics (Haloperidol, Risperidone, Quetiapine, Olanzapine, Clozapine, Aripiprazole)
|
Decreased hypoglycaemic effect
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypoglycaemia
|
Can dangerously lower blood sugar
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Details coming soon
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.